I like LP's suggestion to approving the subgroup and I see collecting post marketing data to keep the approval is very reasonable. In fact FDA has adopted this practice in some instances in the past. In our trial, the statistical strength is vulnerable to getting muddied because of the crossover design went effective such that only 10% remained in the placebo. But we may not be surprised when we unblind to see the crossover patients who came from placebo might have already been evented out and the ones alive today are all from the treatment arm. In that case, all our problems are solved even if FDA did not adopt our subgroup suggestion in the final guidance. While our trial is still unblinded, I see LP's suggestion is protective for us. Overall, FDA is going to allow us comparing the efficacy with historical controls which is what is very good for us because I think FDA realizes crossover design in trials like ours do kill the statistical strength. Hope LP et al release flurry of good news between now and ASM. I think 30% minimum are still alive which is like 60 patients for a minimum of 4 years. I bet they are all from the treatment arm. This OS rate is unprecedented in GBM.